IO Biotech Inc Total Liabilities
IO Biotech Inc total liabilities. Based on the latest financial reports, IO Biotech Inc (IOBT) has total liabilities worth $39.05 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See IOBT defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of IO Biotech Inc (2019–2024)
Total liabilities of IO Biotech Inc from 2019 to 2024. This chart illustrates how IO Biotech Inc's total liabilities have evolved over time, based on quarterly financial data.
IO Biotech Inc Competitors by Total Liabilities
The table below lists competitors of IO Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Moolec Science SA Ordinary Shares
NASDAQ:MLEC
|
USA | $88.21 Million |
|
FRNT Financial Inc
V:FRNT
|
Canada | CA$476.38K |
|
Sangrix Inc.
NASDAQ:SGRX
|
USA | $14.72 Million |
|
Ivory Properties Group Bhd
KLSE:5175
|
Malaysia | RM206.09 Million |
|
Cora Gold Limited
LSE:CORA
|
UK | GBX282.00K |
|
Panther Securities P L C
LSE:PNS
|
UK | GBX79.81 Million |
|
The Hydration Pharmaceuticals Company Ltd
AU:HPC
|
Australia | AU$1.22 Million |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
Indonesia | Rp291.12 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down IO Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see IOBT current and non-current assets.
Liquidity & Leverage Metrics
IO Biotech Inc Total Liabilities Ratios Explained
IO Biotech Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 42.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.98 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IO Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IO Biotech Inc (2019–2024)
The table below shows the annual total liabilities of IO Biotech Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $20.68 Million | +17.82% |
| 2023-12-31 | $17.56 Million | +35.56% |
| 2022-12-31 | $12.95 Million | +24.96% |
| 2021-12-31 | $10.36 Million | +239.80% |
| 2020-12-31 | $3.05 Million | -72.00% |
| 2019-12-31 | $10.89 Million | -- |
About IO Biotech Inc
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand … Read more